News Celgene seals Juno acquisition for $9bn Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy.
Views & Analysis CAR-Ts dominated the agenda at ASH 2017 The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to manage safety issues and bring these costly cellular treatments to patients.
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Janssen jumps into CAR-T field with China’s Legend Biotech J&J has struck a deal with Chinese biotech company Genscript, giving it entry to the global market for CAR-T therapies.
News Gilead goes full throttle on CAR-Ts with $567m acquisition Gilead hopes CDL technology will create therapies targeting solid tumours
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
